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Raman micro spectroscopy study of the interaction of vincristine with 
A549 cells supported by expression analysis of bcl-2 protein 
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Abstract 
 
Understanding the interaction of anticancer drugs with model cell lines is important to elucidate the mode of action of these drugs as well 
as to develop cost effective and rapid screening methods. Raman spectroscopy has been demonstrated to be a valuable technique for high 25 
throughput, noninvasive analysis. The interaction of vincristine with a human lung adenocarcinoma cell line (A549) was investigated 
using Raman micro spectroscopy. The results were correlated with parallel measurements from the MTT cytotoxicity assay, which 
yielded an IC50 value of 0.10 ± 0.03 μM. The Raman spectral data acquired from vincristine treated A549 cells was analysed to 
understand its interaction with the nucleus in the cell and elucidate DNA intercalation. The dose dependent spectral changes in the 
nucleus are analysed by PLS-Jack knifing for the identification of the more significant changes associated with the mode of action of the 30 
drug. Results are correlated with a similar dose dependent expression analysis of the bcl-2 protein, an anti-apoptotic protein associated 
with DNA damage, in the vincristine treated A549 cells using flow cytometry. The results indicate the co-existence of two modes of 
action, microtubule binding at low doses and DNA intercalation at high doses. 
 
Introduction 35 
 
The in vitro study of the interaction of anticancer drugs 
with mammalian cells is important to elucidate the 
mechanisms of action of the drug on its biological targets 
and thereby maximise efficacy. Cancer cell lines can be a 40 
good model to study the effects of these anticancer agents 
and such in vitro studies are in accordance with the EU 
policy of Reduction, Replacement and Refinement (RRR) 
of the protection of animals used for experimental and 
scientific purposes (Directive 2010/63/EU). Another 45 
concern is the requirement of a non-invasive, cost 
effective, rapid screening technique which can analyse the 
samples, ideally without any labelling. Raman micro 
spectroscopy potentially provides these benefits 
1
. In 
addition, Raman spectroscopy can provide high content 50 
information, as it can examine spectral changes in the cell 
membrane, cytoplasm and nucleus of the target cells 
simultaneously and can differentiate the biochemical 
interaction of external agents with the cell from its 
physiological response 
2, 3
. 55 
The potential of confocal Raman micro spectroscopy 
(CRM) for the analysis of biological tissue 
4
 and the effect 
of external agents on the cell 
5-9
 has been demonstrated. 
Moreover, the technique, with its counterpart Fourier 
transform infrared (FTIR) micro spectroscopy, is being 60 
used to explore sub-cellular biochemical structure, as 
demonstrated by its use in studies investigating the action 
of various agents on biological macromolecules as well as 
their interaction with cancer cells 
1-3, 10-17
. 
The use of CRM in studying the biochemical effects of 65 
established, commercially available anticancer drugs may 
be helpful therefore in order to validate its use for the 
evaluation of the novel anticancer agents. To this end, such 
an approach was demonstrated for the action of cis-platin 
with lung cells in vitro 
2, 3
. The study utilized multivariate 70 
regression and feature selection techniques to correlate 
spectral changes with drug dose and cell viability, as 
measured using a standard cytotoxic assay. 
A proposed primary mode of action of vincristine is 
through its binding to tubulin monomers in the cytoplasm, 75 
which leads to a change in the dynamics of the microtubule 
assembly and prevention of the formation of bi-polar 
spindles 
18
, necessary for the proper segregation of the 
duplicated chromosomes and ultimately cell division. 
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Additionally, however, vincristine has been reported to 
interact directly with DNA in acellular studies, as observed 
using techniques such as Atomic Force Microscopy 
19
, 
Fluorescence image microscopy 
20
 and FTIR spectroscopy 
21
, which indicate that it acts as an intercalator. The 5 
combined evidence raises the question as to whether 
vincristine causes cell death only by disturbing the 
dynamics of the microtubule assembly or whether the 
DNA damage caused by this anticancer agent also 
contributes to its efficacy. 10 
The purpose of this study is to further elucidate the 
interaction of the drug on a cellular level, as well as the 
cellular response pathways, using CRM to characterise 
biochemical changes on the subcellular level. To support 
the spectroscopic investigation, the expression of bcl-2 15 
protein as a result of vincristine treatment is explored using 
flow cytometry. Bcl-2 is an anti-apoptotic protein which is 
generated as a direct result of DNA damage, and is thus 
involved in the regulation of cell death and serves as an 
indicator of genotoxic stress to the cell 
22, 23
. The 20 
comparison of the observations of changes to the Raman 
signatures of nucleus of the A549 cells as a result of 
vincristine exposure as compared to the unexposed control, 
as well as the changes in the expression profile of bcl-2, 
may lead to elucidation as to whether DNA damage 25 
contributes to the mode of action of this anticancer agent. 
 
 
Experimental 
MTT assay 30 
Vincristine was purchased from Sigma Aldrich, Ireland, in 
the form of vincristine sulphate (V8388) and a stock 
solution was prepared in distilled water. Working solutions 
were prepared in the cell culture media. 
MTT was obtained from Sigma Aldrich, Ireland. The MTT 35 
assay was performed in triplicate according to a method 
reported previously 
24
 with a slight modification. The 
exposure of A549 cells to vincristine was done for 96-
hours, over a wide range of concentrations (0.01-10 μM) to 
establish the half maximal inhibitory concentration (IC50) 40 
and the appropriate range over which to conduct the 
analysis. 
The MTT measurement protocol was as follows. Cells 
were cultured in 96-well plates (Nunc, Denmark) at a 
density of 2  103 cells per well in Dulbecco’s Modified 45 
Eagle Medium-F12 (DMEM) with all the supplements as 
listed above. After 24 hrs of initial cell attachment, the 
plates were washed with 100 μl/well phosphate buffered 
saline (PBS) and were treated with varying concentrations 
of vincristine in the range of 0.01 μM -10 μM (including a 50 
separate unexposed control sample). Following a 96-hour 
exposure period, the cells were rinsed with PBS and 100 μl 
of fresh medium (without supplements) were added to each 
well. A volume of 10 µl of MTT (5mg/ml) prepared in 
PBS was then added to each well and the plates were 55 
incubated for 3 hrs at 37 °C in a 5% CO2 humidified 
incubator. After this incubation period, the medium was 
discarded, the cells were washed with 100 μl of PBS and 
100 μl of Dimethyl Sulphoxide (DMSO) were added to 
each well to extract the dye. The plates were then shaken 60 
240 times per minute for 10 min and the absorbance was 
measured at 570 nm using a micro plate reader (Tecan 
Genios, Grodig, Austria). Six replicate wells were used for 
each exposure. 
 65 
Raman micro spectroscopy 
In this work, CRM was conducted with a Horiba Jobin-
Yvon, LabRam HR800 instrument using a 785 nm laser as 
source. Spectra were taken in the range from 600 cm
-1
 to 
1800 cm
-1
 with a confocal hole diameter of 100μm. A x100 70 
water immersion objective was used to focus the laser on 
the sample, immersed in 0.9% saline, yielding a spot size 
of ~1 µm. 
For CRM, cell samples were cultured on quartz substrates 
according to a protocol outlined elsewhere 
9
. Briefly, 75 
quartz coverslips were coated with a 2% w/v gelatin-water 
solution and maintained at 4 °C for 6 hrs to allow 
polymerization of the gelatin on the substrate. 
Subsequently, 2.5  103 A549 cells were attached to the 
substrates for a 48 hour period, and were exposed to 80 
vincristine concentrations in the range of 0.01 μM -10 μM 
for a 96-hour period (together with a non-exposed control 
sample). After the exposure period, the cells were fixed in 
4% formalin for 10 minutes and were stored in 0.9 % 
physiological saline solution at 4 °C until the Raman 85 
analysis was performed 
25
. All samples were prepared in 
triplicate.  
For spectral acquisition, the laser power was 
approximately 70 mW at the sample. Spectra were taken in 
the range from 600 cm
-1
 to 1800 cm
-1
 with a confocal hole 90 
diameter of 100μm. A 100 water immersion objective 
was used to focus the laser on the sample, immersed in 
0.9% saline, yielding a spot size of ~1 µm. Multiple 
spectra were recorded from the nuclear portion, visually 
identified using the optical microscope of the instrument, 95 
of a total of 60 cells at each exposure level. The point 
spectra were recorded from the cell nuclei of the sixty 
different A549 cells for control as well as exposed 
samples. 
 100 
Data analysis 
 
All spectral analysis was performed in the Matlab 7.2 (The 
Mathworks Inc.) environment employing the PLS Toolbox 
5.0.3 (Eigenvector Research, Wenatchee, WA) and 105 
algorithms developed in-house. Subsequently, the spectra 
were smoothed with a Savitsky-Golay filter (order 5, 13 
point window), and the quartz signal background was 
subtracted using algorithms developed in-house. Prior to 
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analysis, the spectra were also vector normalized and a 
fifth order polynomial was fitted to the spectra to remove 
any residual spectral baseline. Outlying spectra were 
removed using Grubb’s filtering 26.  
PLS Jack-knifing was employed as a multivariate feature 5 
selection technique 
27-29
. The PLS regression algorithm 
seeks to develop a model that relates the spectral data (X-
matrix) to a series of targets (Y-matrix, e.g. concentration 
of reaction product or analyte) according to the equation 
Y=XB+E, where B is a matrix of regression coefficients 10 
and E is the regression residual. The Y-matrix here 
consisted of values of the concentration of vincristine to 
which the cells were exposed, or the measured level of cell 
viability from the MTT assay. The PLS Jack-knifing 
method developed by Westad and Martens was then used 15 
to determine the spectral features that were statistically 
significant at a particular level of confidence using t-
testing of the regression coefficients, B 
29
. The Raman 
band assignments used in interpretation of the spectral 
features were taken from the literature 
9, 15, 30-32
. 20 
 
Flow cytometry 
 
For the culture of A549 cells, the materials and protocols 
used were the same as those described above for Raman 25 
spectroscopy measurements. The bcl-2 antibody labelled 
by FITC with an IgG1 isotype control was purchased from 
BD biosciences (BD 556357). The cytoperm/ cytofix 
fixation/ permeabilization kit was purchased from BD 
biosciences (BD 554714).  30 
The A549 cells were cultured in tissue culture flasks 
(Nunc, Denmark) at a density of 1  105 cells in DMEM-
F12 medium with all the supplements as described earlier. 
After 24 hrs of initial cell attachment, the plates were 
washed with PBS and were treated with varying 35 
concentrations of vincristine in the range from 0.01 μM- 
10μM (including a separate unexposed control sample). 
Following a 96-hour exposure period, the cells were 
trypsinised and collected in an Eppendorf, 1x10
6
 cells per 
sample. The cells were washed twice with ice cold 40 
Dulbecco's Phosphate-Buffered Saline (DPBS) buffer 
(containing protein and NaN3), gently resuspended and 
centrifuged (250-300 g). The fixation buffer (250μl) was 
added to each sample, and the process was followed by 
gentle pipetting and incubation for 30 minutes at 4 ˚C. The 45 
fixed cells were washed and suspended in the stain buffer. 
This was followed by the addition of 100 μl of the 
permeabilization buffer and incubation for 15 minutes at 
room temperature. The samples were then washed twice 
with 1ml of the perm wash buffer and centrifuged at 250-50 
300 g for 5 minutes at 4 ˚C, and the cells were suspended 
in 50 μl of the perm wash buffer and the diluted antibody 
was added. This was followed by incubation of the 
samples for 60 minutes, on ice and in the dark. Then cells 
were washed twice with the perm wash solution to remove 55 
the unbound antibody. The tubes were inverted and blotted 
to remove the supernatant. The samples were resuspended 
in stain buffer and analyzed by flow cytometry. 
The expression analysis of the bcl-2 protein in A549 cells 
due to the action of the vincristine was performed using a 60 
Partec Flow Cytometer (Partec UK Limited, U.K.) and the 
data analysis was performed using Summit software 
(Version 4.3, DAKO, Denmark). 
 
Results 65 
IC50 for vincristine 
 
The MTT results for the cytotoxicity measurement of 
vincristine in A549 cells are presented in Figure 1. The 
level of viability in each sample was normalised to that of 70 
the control sample. The Inhibitory Concentration (IC50) 
value was derived from the data by a fit of the Hill 
equation, f(x) = min + (max-min)/(1+(x/IC50)^n) and found 
to be 0.10±0.03 μM. The primary purpose of the MTT 
assay was to determine the exposure range over which the 75 
maximum variation occurs in the cellular response, and 
thus the optimum range to probe the associated changes to 
the spectral response. 
 
Vincristine Concentration (M)
0.001 0.01 0.1 1 10
N
o
r
m
a
li
s
e
d
 V
ia
b
il
it
y
0.0
0.2
0.4
0.6
0.8
1.0
80 
 
Figure 1 Viability of the A549 cells measured by MTT absorbance at 96 
hours after exposure to vincristine. Error bars denote the standard error on 
the mean at each concentration. 
 85 
 
Interaction of vincristine with the nucleus of A549 cells 
 
To identify any biochemical changes caused by the direct 
action of vincristine on the nucleus, the Raman spectra of 90 
the nucleus of A549 cells exposed to the range of 
concentrations of vincristine were recorded. The nuclear 
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spectra of the mean control, and vincristine exposed 
samples are shown in Figure 2. The major changes 
observed in the spectra of the nucleus of A549 cells are in 
the Raman bands of the DNA bases, including thymine 
(669 cm
-1
and 1253 cm
-1
), adenine (728 cm
-1
), guanine 5 
(1317 cm
-1
) and cytosine (783 cm
-1
). These changes can be 
attributed to the action of the vincristine within the nucleus 
of the A549 cells and specifically due to interaction with 
the DNA. As the concentration of the drug exposure 
increases, a decrease in the intensities of the bands 10 
associated with the DNA bases is observed. This is 
consistent with the results of the intercalation of the 
ethidium bromide, a well known DNA intercalator, into 
calf thymus DNA studied by Raman spectroscopy 
33
. 
Conversely, 
21
 have reported an increase in the intensities 15 
of the bands due to DNA bases while investigating the 
effect of very high concentrations, ranging from 200-300 
μM, of vincristine on calf thymus DNA, acellularly, with 
the help of FTIR spectroscopy. It should be noted, 
however, that these concentrations are significantly higher 20 
than the maximum of the range employed in this study (10 
μM), and the clinically relevant IC50 (0.1 μM). The 
decrease in the intensities of the vibrational features 
ascribed to these DNA bases and most importantly the 
conformational changes of the B-form DNA into A-form, 25 
as indicated by the continuous decrease in the intensity of 
the Raman band at 827 cm
-1
 and concomitant increase in 
the intensity of the A-form DNA (811 cm
-1
), due to the 
action of vincristine, provides evidence of intracellular 
intercalation of vincristine into the DNA. Moreover, in the 30 
control spectra of the nucleus of A549 cells, the CH2 
scissoring mode, observed as a sharp band at 1422 cm
-1
, is 
considered as an important Raman marker of the B-form 
DNA and is found to be much more broader and lower in 
peak intensity in the A-form DNA 
34
. This trend is clearly 35 
observable in the decreased contributions of this band in 
exposed samples in Figure 2, again indicating 
conformational changes in the B-form DNA in favour of 
the A-form.  
 40 
Interestingly, in comparison to the effects on the nuclear 
Raman spectrum as a result of exposure to cisplatin, a 
known DNA groove binder, 
2
, the changes observed in the 
conformation of the B-form of DNA, the dominant form of 
cellular DNA, are more prominent. These changes, 45 
including decreases in the Raman intensities of the bands 
due to DNA bases and changes in the DNA conformation 
are the important Raman markers of DNA intercalation 
33, 
35-37
. Changes in the phosphodiester linkages, the O-P-O 
stretching vibrations of the DNA, are also observed at 50 
1095 cm
-1
 along with a shift towards lower wavenumber at 
the higher concentrations including 3 and 10 μM. These 
changes indicate that vincristine also has the ability to bind 
to the DNA externally, in addition to its insertion into the 
DNA helix 
21
, as observed in the case of cisplatin studies 
2
. 55 
Raman bands related to proteins are also observed, 
including those at 699 cm
-1
 and 718 cm
-1
, 879 cm
-1
, 1556 
cm
-1
 (tryptophan ring breathing), 1265 cm
-1
 (amide-III, -
helix), 1302 cm
-1
 (CH2 deformation), and 938 cm
-1
 (C-C 
stretching), 959 cm
-1
 (CH3 deformation) and 1060 cm
-1
 (C-60 
N stretching). The intensities of all these Raman bands 
increase as a result of an increase in the concentration of 
the exposures of the vincristine, particularly at the higher 
concentrations of this anticancer drug. This may be due to 
the fact that, after the conformational changes caused in 65 
the DNA by the anticancer drug binding, high mobility 
group proteins bind to the intercalation site and prevent 
repair by nuclease enzyme excision 
38
. Furthermore, the 
proteins which are present in the nucleus, essentially 
required for the DNA strand packaging, may be more 70 
exposed due to the DNA strand opening which is caused 
by the intercalation of the vincristine. 
It should be noted that the Raman spectral changes 
observed in Figure 2 and discussed above can not 
unambiguously be attributed specifically to either the 75 
direct chemical binding of the vincristine to the DNA in 
the nucleus of the A549 cells or the subsequent 
physiological response of the cells to the drug. Therefore, 
PLS-Jack knifing was employed in an attempt to 
differentiate the chemical and the physiological effect of 80 
the drug by regressing the Raman spectral data from the 
nucleus of A549 cells against the exposure concentrations, 
compared to a similar regression against the cell viability 
end points 
2
. 
 85 
PLS-Jack knifing analysis was carried out on the Raman 
spectral data from the nucleus of control and exposed 
A549 cells (over the full dose range) to further understand 
and confirm the mode of action of vincristine as an 
intercalative agent with DNA, and to identify the 90 
fingerprints of this interaction within the cellular spectra of 
exposed cells. The regression co-efficients were obtained 
by PLS-Jack knifing for separate regressions against 
vincristine concentrations and against the cell viability, as 
determined using the MTT assay. To reveal spectral 95 
changes that are most statistically significant with respect 
to regression against either endpoint, a t-test (p<0.001) was 
applied to the PLS-Jack knifing results, and the spectral 
features identified by this process are highlighted by 
vertical bands in Figure 3. The spectral bands identified 100 
and their assignments are tabulated in the Supplementary 
Information. The PLS regression of the nuclear data 
against vincristine concentrations identified a number of 
spectral features, labelled in Figure 3 A, related to the 
DNA bases, including guanine (1209-1211 cm
-1
, 1289-105 
1309 cm
-1
, 1320-1322 cm
-1
), thymine (673-678 cm
-1
, 733-
737 cm
-1
, 1251-1257 cm
-1
, 1378-1381 cm
-1
) and cytosine 
(773-778 cm
-1
, 1166-1173 cm
-1
, 1298-1309 cm
-1
). These 
features are identified only in the regression against the 
concentration of the vincristine. Moreover, changes 110 
associated with the phosphodiester linkage, O-P-O of the 
DNA, are also highlighted (1062-1065 cm
-1
 and 1075-1090 
cm
-1
), confirming the indications from Figure 2 that 
vincristine, in addition to the intercalation mode of action, 
can also bind to the DNA externally. 115 
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The changes which are observed only in the regression of 
the nuclear data against cell viability, Figure 3 (B), include 
C-C stretching of tyrosine residues (637-643 cm
-1
), 
tryptophan ring breathing (696-700 cm
-1
), amide-III (1250-
1256 cm
-1
), CH in plane bending of tyrosine (842, 844 cm
-
5 
1
, 1176-1177 cm
-1
) and CH deformation (1340-1343 cm
-1
), 
which can be assigned to proteins. These features 
potentially originate from the high mobility group proteins 
which are activated to prevent further damage to the cell 
and to repair by nuclease enzyme excision 
38
. 10 
Comparing the regression co-efficients obtained by PLS-
regression analysis of the Raman spectral data against the  
 
 
 15 
Figure 2: Mean spectrum of the nucleus of control and exposed A549 cells to 0.01-10 M vincristine. 
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 5 
Figure 3 Feature selection in PLS-Jack knifing of Raman spectra of the A549 cell nucleus against (A) vincristine concentrations and (B) against cellular 
viability. The shaded areas in grey denote the statistically significant features selected using PLS Jack-knifing with a t-test (p<0.001) of regression 
coefficients (shown in red with associated standard error shaded about them). This demonstrates that the spectral data contains features associated with the 
biochemical effect of vincristine on the nucleus (A) and the associated effect on cellular viability (B). 
 10 
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concentrations of the exposures of the vincristine (which 
highlight the primary biochemical effect of the action of 
the agent) with those obtained via regression against cell 
viability (which highlight biochemical markers of the 
change in the viability of the cell), very different spectral 5 
features are selected as being statistically significant. This 
allows the differentiation of the biochemical changes 
caused in the A549 cells due to the DNA binding of the 
vincristine from the physiological response of the cells. It 
is noted that the PLS-Jack-knifing identifies a range of 10 
spectral features of relevance in the regression against each 
set of targets, the relevance of which appears statistically 
justified by the application of the t-test of the regression 
coefficients. Karaman et al. have however demonstrated 
that, in comparison to Sparse PLSR, the PLS- Jack knifing 15 
method was prone to selecting uninformative variables 
39
. 
Ultimately the accuracy, sensitivity and specificity of the 
method should be validated using simulated datasets 
12
. 
 
It is also noted that as a function of concentration, the cells 20 
which remain alive and are therefore probed by CRM 
potentially include those which have not yet been exposed, 
or have not yet responded to the drug, at low 
concentrations and potentially cells which are immune at 
higher concentrations. Nevertheless, the MTT assay is a 25 
measure of mitochondrial activity of the cell population, 
and the spectral markers identified by regression of the 
CRM data against the MTT target should provide a similar 
measure of this as an indication of viability for in vitro 
screening, in a label free manner. Ideally, to examine the 30 
true cellular response, CRM should be performed on live 
cells with subcellular resolution in a time resolved fashion. 
 
Expression of bcl-2 protein in A549 cells treated with 
vincristine analysed by Flow cytometry 35 
Raman spectroscopic analysis of the nucleus of exposed 
cells clearly indicates the interaction of vincristine with 
nuclear DNA. The bcl-2 protein is an anti-apoptotic protein 
40, 41
, and is involved in blocking DNA damage induced 
apoptosis 
42, 43
. Changes in the expression of bcl-2 after 40 
exposure of the A549 cells to vincristine would indicate 
the involvement of the DNA damage pathway in the mode 
of action of the drug. Enhanced expression would point 
towards the development of resistance towards DNA 
damage induced cell death and decreased expression vice 45 
versa. Therefore, simultaneous observation of bcl-2 as a 
result of DNA damage and reduced cellular viability would 
point towards alternative mechanisms of cell death. 
The results of flow cytometry for the expression of bcl-2 
protein in A549 cells as a result of the treatment with 50 
various concentrations of vincristine ranging from 0.01 
μM-10 μM, are shown in Figure 4. The results show that, 
due to the exposure of different concentrations of 
vincristine to A549 cells, the level of bcl-2 protein 
compared to control increases steadily up to a 55 
concentration of 5 µM, whereupon it decreases. These 
results indicate the involvement of the bcl-2 protein and 
therefore DNA damage in the mode of action of 
vincristine. A549 cells do not intrinsically express marked 
levels of bcl-2 protein as shown by 
23, 44
. The up-regulation 60 
of the bcl-2 protein is therefore a response of the cell to the 
external agent which causes damage to the nuclear DNA. 
A similar expression profile, up regulation followed by 
down regulation of the bcl-2 protein, was observed while 
studying the effect of the anaesthetic halothane, considered 65 
as a DNA damaging agent, on A549 cells and this 
expression profile has been reported to be responsible for 
the resistance to apoptosis at low doses, whereas induced 
apoptosis due to DNA damage becomes prominent upon 
down regulation of bcl-2 at high doses 
23
. In the current 70 
study, the Raman spectral data also indicates that 
vincristine binds to the cellular DNA by intercalation, so 
here bcl-2 up regulation may be in response to the DNA 
damage caused by the drug 
45
. This may lead to the 
conclusion that vincristine also binds to DNA by 75 
intercalation, causes up regulation of bcl-2, whose anti-
apoptotic function helps to delay the response of the cells 
at low doses (development of resistance). The bcl-2 
expression is observed to decrease at doses > 5 µM, 
however, indicating that above these doses the cells are 80 
susceptible to apoptosis induced by DNA damage.  
The Raman results give a clear indication that the 
documented acellular interactions of vincristine with DNA 
also occur intracellularly. However, the bcl-2 results 
indicate a resistance to apoptosis induced by DNA damage 85 
at vincristine doses <5 µM. Critically however, this dose is 
significantly higher than the IC50 value of 0.10 ± 0.03 μM, 
measured by the MTT assay. Therefore, the dominant 
mechanism of cell death at lower doses cannot be ascribed 
to DNA damage, but rather to the mechanism of tubulin 90 
binding leading to a change in the dynamics of the 
microtubule assembly and prevention of the formation of 
bi-polar spindles 
18
. 
 
 95 
 
Figure 4 Expression level of bcl-2 shown as increase in the fluorescence, 
due to the treatment of different concentrations of vincristine in A549 
cells determined by flow cytometry. 
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Conclusion 
 
The Raman analysis confirms that vincristine interacts with 
the nuclear DNA resulting in significant changes to the 
spectroscopic markers of DNA which are characteristic of 5 
both intercalation and external binding. Changes observed 
in the DNA related features include those of cytosine (783 
cm
-1
), guanine (1318 cm
-1
), thymine (1375 cm
-1
), O-P-O of 
DNA (1095 cm
-1
). Notably, the changes in the B-form 
DNA (827 cm
-1
) in favour of A-form conformation and B-10 
form DNA (1422 cm
-1
) are prominent and systematic as a 
function of vincristine exposure. These changes can be 
taken as the Raman markers of DNA intercalation. 
Expression of bcl-2 in A549 cells as a result of exposure to 
vincristine is found to be concentration dependant and 15 
increases with increasing concentration to a maximum, 
whereafter levels are reduced at higher doses. The up-
regulation of bcl-2 is the response of the cell to the external 
agent which causes damage to the DNA and affects an 
inhibition of apoptosis. In the current study, the Raman 20 
spectral data indicated that vincristine binds the cellular 
DNA by intercalation, so here bcl-2 up regulation is in 
response to the DNA damage caused by the drug and 
confirms the findings of the Raman study for the 
interaction of this drug with nucleus of the A549 cells. 25 
Nevertheless, the MTT assay clearly indicates loss of 
viability at these doses, pointing to microtubule damage as 
the primary mode of action in this region. The study 
demonstrates the potential of Raman spectroscopy, not 
only for the fingerprinting and screening of cellular 30 
responses but for the elucidation of mechanisms of action 
of external agents. 
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Supplementary information: 
 15 
Spectral ranges (cm
-1
) assignments 
621-626 C-C twisting of phenyl 
629-633 C-C stretching 
635-637 C-C stretching 
637-643 C-C stretching of tyrosine residues 
655-656 alanine 
673-678  thymine 
 696-700 tryptophan ring breathing 
703-704 tryptophan 
708-711 tyrosine 
719-727 Adenine/tryptophan 
733-737 thymine 
748-750 thymine 
763-766 thymine 
769-773 alanine 
773-778 tryptophan 
784-795 cytosine 
797-808 O-P-O of DNA (A-form) 
828-829 O-P-O of DNA (B-form) 
842-844 CH in plane bending of tyrosine 
849-857 C-C stretching 
861-864 tryptophan 
893-898 Deoxiribose of DNA 
904-906 valine 
936-939 C-C stretching 
944-947 valine 
1000-1007 Phenyl alanine 
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1021-1026 CH in plane bending 
1030-1033 CH in plane bending 
1055-1058 C-N stretching 
1062-1065 O-P-O of the DNA 
1075-1090 O-P-O of the DNA 
1114-1121 C-N stretching 
1142-1148 C-C stretching 
1166-1173 cytosine 
1176-1177 CH in plane bending of tyrosine 
1194-1196 tyrosine 
1209-1211 guanine 
1251-1257 thymine 
 1250-1256 amide-III 
1261-1261 Amide-III β-sheet 
1263-1271 Amide-III β-sheet 
1276-1280 Amide-III α-sheet 
1289-1309 cytosine 
1320-1322
 
 guanine 
1331-1332 tryptophan 
1347-1360 CH3 stretching 
1340-1343 CH deformation 
1378-1381 thymine 
1424-1428 CH deformation 
1453-1461 CH deformation 
1468-1470 histidine 
1503-1505 C=C stretching 
1545-1559 tryptophan 
1566-1572 tryptophan 
1596-1597 C=C bending 
1631-1633 histidine 
1643-1645 C=C stretching 
1663-1665 amide-I 
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1702-1709 thymine 
1727-1731 C=O ester 
1783-1786 C-C bending 
 
